NEJM: Siglec-8 monoantigen-resistant Lirentelimab significantly relieves eosinophilic gastritis and eosinophilic enteritis.

Biotech company Allakos has announced that its single anti-lirentelimab (AK002) targeting Siglec-8 is multi-centered and random in patients with acidic gastritis and enigma The double-blind, placebo-controlled Phase II clinical study was published in the New England Journal of Medicine (NEJM) under the title Anti-Siglec-8 Antibody for Eosinophilic Gastritis and Duodenitis.
results showed clinical and statistically significant improvements in all dose groups of AK002 at pre-specified primary and secondary endpoints, including the count of acidic granulocytes in gastrointestinal tissue and disease symptoms reported by patients, compared to placebo.
AK002 reaches all major and secondary end points (Photo: Anti-Siglec-8 Antibody for Eosinophilic Gastritis and Duodenitis. NEJM. 2020) AK002 Symptoms of the disease improved significantly after treatment (Photo: Anti-Siglec-8 Antibody for Eosinophilic Gastritis and Duodenitis. NEJM. 2020) Siglec-8 is an inhibitory subject of selective high expression in mature eosinophils and fat cells.
overactivation of eosinophils and hypertrophic cells has been shown to be a key driver of eosinophilic gastritis and acidophilitis.
AK002 as a target Siglec-8 IgG1 monoantigen, through antibody-mediated cytotoxicity and induced apoptosis, the consumption of eosinophils.
AK002 mechanism of action schematic acidophilitis and eosinophilic hemophilitis are serious inflammatory diseases characterized by the presence of high levels of acidic granulocytes in the stomach or tifle intestine.
these diseases can be seriously misdiagnosed compared to other gastrointestinal diseases.
there is no specific treatment, systemic steroid hormone therapy can improve symptoms, but due to the side effects, generally can not be long-term use of steroid hormone therapy.
.